Dinah Marçal Verdugo Duarte (381C-ABE6-9ADD)

Curriculum Vitae

Dinah Marçal Verdugo Duarte

Identification

Personal identification

Full name: Dinah Marçal Verdugo Duarte

Citation names

Duarte, Dinah

Author identifiers

Ciência ID: 381C-ABE6-9ADD
ORCID iD: 0000-0002-2595-5263

Education

	Degree	Classification
2019 - 2019 Concluded	Advanced PhD Courses of the PhD Programme of Medicines and Pharmaceutical Innovation (i3DU) (Curso de doutoramento (conclusão de unidades curriculares)) Major in Non-clinical efficacy and safety Universidade de Lisboa Faculdade de Farmácia, Portugal	18/20
2019 - 2019 Concluded	Advanced PhD Courses of the PhD Programme of Medicines and Pharmaceutical Innovation (i3DU) (Curso de doutoramento (conclusão de unidades curriculares)) Major in Epidemiology research in drug lifecycle Universidade de Lisboa Faculdade de Farmácia, Portugal	19/20
2015 - 2015 Concluded	Specialist with recognized experience and professional competence, in the area of Pharmaceutical Sciences, according to Decree-Law 74/2006 (article 3), as amended by Decree-Laws 107/2008, 230/2009 and 115/2013. (Título de especialista) Major in Pharmaceutical Sciences Universidade Lusófona, Portugal
2015 - 2015 Concluded	Advanced Program on Pharmaceutical Management (APROPHARMA) (Pós-Graduação) Major in Pharmaceutical Management Universidade de Lisboa Faculdade de Farmácia, Portugal
2012 - 2012 Concluded	Training Programme in Public Management (FORGEP) (Pós-Graduação) Major in Public Management Direção-Geral da Qualificação dos Trabalhadores em Funções Públicas, Portugal	17/20
2007 - 2007 Concluded	Regulation and Evaluation of Medicines and Health Products (Mestrado) Major in Pharmacotoxicology Universidade de Lisboa Faculdade de Farmácia, Portugal	Excellent
2006 - 2006 Concluded	Regulatory Affairs Specialist (Título de especialista) Major in Regulatory Affairs Ordem dos Farmaceuticos, Portugal
2006 - 2006 Concluded	Hospital Pharmacy Specialist (Título de especialista) Major in Hospital Pharmacy Ordem dos Farmaceuticos, Portugal
1985 - 1991 Concluded	Doctor of Pharmacy Degree (PharmD) (Licenciatura) Major in Ambulatory and Hospital Pharmacy Universidade de Lisboa Faculdade de Farmácia, Portugal	15/20

Affiliation

Teaching in Higher Education

	Category Host institution	Employer
2017 - Current	Invited Assistant Professor (University Teacher)	Universidade de Lisboa Faculdade de Farmácia, Portugal
	Universidade de Lisboa Faculdade de Farmácia, Portugal
2000 - Current	Assistant Professor (University Teacher)	Universidade Lusófona, Portugal
	Universidade Lusófona de Humanidades e Tecnologias Escola de Ciências e Tecnologias da Saúde, Portugal

Positions / Appointments

	Category Host institution	Employer
2018 - Current	COMP Representative in the EMA’s group “Human Scientific Committees Working Party With Healthcare Professionals Organisations (HCPWP) ”, 2013-2015 (CHMP representative) and COMP representative since 2	Infarmed Autoridade Nacional do Medicamento e Produtos de Saúde IP, Portugal
	European Medicines Agency, Netherlands
2015 - Current	Non-clinical Assessor at Scientific Evaluation Unit , Directorate for the Evaluation of Medicinal Products	Infarmed Autoridade Nacional do Medicamento e Produtos de Saúde IP, Portugal

2015 - Current	Committee of Orphan Medicinal Products (COMP) member from Portugal, at European Medicines Agency (EMA), since 2015	Infarmed Autoridade Nacional do Medicamento e Produtos de Saúde IP, Portugal
	European Medicines Agency, Netherlands
2013 - Current	Expert member at Paediatric Committee (PDCO) “Non-clinical Working Group” (NcWG), since 2013	Infarmed Autoridade Nacional do Medicamento e Produtos de Saúde IP, Portugal
	European Medicines Agency, Netherlands
2015 - 2018	COMP Representative in the Steering Group of ENCePP (European Network of Centres for Pharmacoepidemiology & Pharmacovigilance), 2015-2018	Infarmed Autoridade Nacional do Medicamento e Produtos de Saúde IP, Portugal
	European Medicines Agency, Netherlands
2011 - 2017	Organic Unit Director	Infarmed Autoridade Nacional do Medicamento e Produtos de Saúde IP, Portugal

2012 - 2015	Committee for Medicinal Products for Human Use (CHMP) alternate member from Portugal, at EMA, 2012-2015	Infarmed Autoridade Nacional do Medicamento e Produtos de Saúde IP, Portugal
	European Medicines Agency, Netherlands

Outputs

Publications

Book chapter

Duarte, Dinah. "A Regulatory and Safety Perspective on Medical Devices". 1815-1826. {IGI, 2021.
10.4018/978-1-7998-3479-3.ch125

Journal article

Duarte, Dinah. "Patient Preferences for Multiple Myeloma Treatments: A Multinational Qualitative Study". Frontiers in Medicine 8 (2021): http://dx.doi.org/10.3389/fmed.2021.686165.
10.3389/fmed.2021.686165
Duarte, Dinah. "Analysis of Medical Device Alerts Issued by the Portuguese Medicines Agency: Scoping the Purpose of New Regulatory Recommendations". Acta Médica Portuguesa 34 3 (2021): 201-201. http://dx.doi.org/10.20344/amp.13419.
10.20344/amp.13419
Duarte, Dinah. "The translational value of animal models in orphan medicines designations for rare paediatric neurological diseases". Regulatory Toxicology and Pharmacology 118 (2020): 104810-104810. http://dx.doi.org/10.1016/j.yrtph.2020.104810.
10.1016/j.yrtph.2020.104810
Duarte, Dinah. "Evaluation of Juvenile Animal Studies for Pediatric CNS-Targeted Compounds: A Regulatory Perspective". International Journal of Toxicology (2019): http://dx.doi.org/10.1177/1091581819883569.
10.1177/1091581819883569
Duarte, Dinah. "Nonclinical data supporting orphan medicinal product designations in the area of rare infectious diseases". Drug Discovery Today (2019): http://dx.doi.org/10.1016/j.drudis.2019.10.015.
10.1016/j.drudis.2019.10.015
Duarte, Dinah. "Nonclinical data supporting orphan medicinal product designations: lessons from rare neurological conditions". Drug Discovery Today (2018):
https://doi.org/10.1016/j.drudis.2017.09.015
Duarte, Dinah. "Strengthening standards and collaboration to support medicines evaluation: Ten years of the European Network of Centres for Pharmacoepidemiology and Parmacovigilance (ENCePP)". Pharmacoepidemiology and Drug Safety (2018):
10.1002/pds.4381
Duarte, Dinah. "An overview of pharmaceutical excipients: safe or not safe?". Journal of Pharmaceutical Sciences (2016):
10.1016/j.xphs.2016.03.019
Duarte, Dinah. "Rebuttal to Dr. Andrew and Dr. Keller letter to the Editor on “Juvenile Animal Studies in Oncology Medicines for Children”". Reproductive Toxicology (2016):
10.1016/j.reprotox.2016.05.013
Duarte, Dinah. "Use of Juvenile Animal Studies to Support Oncology Medicine Development in Children". Reproductive Toxicology (2015):
10.1016/j.reprotox.2015.05.005
Duarte, Dinah. "Juvenile animal studies in the development of pediatric medicines: experience from European medicines and pediatric investigation plans". Birth Defects Research Part B: Developmental and Reproductive Toxicology (2011): http://dx.doi.org/10.1002/bdrb.20299.
10.1002/bdrb.20299

Activities

Association member

	Society Organization name	Role
2018 - Current	Portuguese Hub from EATRIS-ERIC: European infrastructure for translational medicine - European Research Infrastructure Consortium	National Coordinator of the Portuguese Hub from EATRIS-ERIC: European infrastructure for translational medicine - European Research Infrastructure Consortium, since 2018.

Committee member

	Activity description Role	Institution / Organization
2018 - Current	Member of the Scientific Committee of Orphanet Portugal (The portal for rare diseases and orphan drugs), since 2018. Member	Direcção-Geral da Saúde, Portugal
2017 - Current	Member of the Portuguese National Commission for Women, Children and Adolescents (Comissão Nacional da Mulher, Criança e Adolescente - CNMCA), from the Directorate-General of Health (Direção Geral de Saúde - DGS) - Despacho nº 4492/2017 de 25 de maio, since 2017 Member	Direcção-Geral da Saúde, Portugal
2016 - 2017	Member of the Technical Monitoring Group of the Portuguese Delegation to the Programmatic Committee of the Societal Challenge (Grupo Técnico de Acompanhamento (GTA) da Delegação Portuguesa ao Comité Programático do Desafio Societal 1 - (DS1) from Horizon 2020 (H2020) - “ Health, Demographic Change and Welfare”, 2016-2017 Member	Fundação para a Ciência e a Tecnologia, Portugal
2013 - 2016	Member of the Coordinating Committee for the Treatment of Lysosomal Storage Disorders (Comissão da Comissão Coordenadora do Tratamento das Doenças Lisossomais de Sobrecarga - CCTDLS), of the National Institute of Public Health (INSA), Ministry of Health, 2013-2016 Member	Instituto Nacional de Saúde Doutor Ricardo Jorge, Portugal

Evaluation committee

	Activity description Role	Institution / Organization	Funding entity
2016 - Current	Member of the Portuguese scientific Evaluation Board of Medicines (Comissão de Avaliação de Medicamentos – CAM) of the Portuguese National Authority of Medicines and Health Products - INFARMED, I.P., Despacho nº 13120/2016 de 2 de novembro, since 2016 Evaluator	Infarmed Autoridade Nacional do Medicamento e Produtos de Saúde IP, Portugal
2013 - 2014	Member of the Portuguese Pharmacopeia Commission (Comissão da Farmacopeia Portuguesa) of the Portuguese National Authority of Medicines and Health Products - INFARMED, I.P., 2013-2014. Evaluator	Infarmed Autoridade Nacional do Medicamento e Produtos de Saúde IP, Portugal